Search Result

Results for "

human PPARα

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (4) Arrestin (1) Autophagy (7) Calcium Channel (2) Cytochrome P450 (6) DNA/RNA Synthesis (1) Drug Intermediate (2) Endogenous Metabolite (2) Epoxide Hydrolase (3) ERK (3) FLAP (3) Free Fatty Acid Receptor (1) GPR35 (1) Histone Demethylase (1) Isotope-Labeled Compounds (5) Keap1-Nrf2 (1) Leukotriene Receptor (3) Lipoxygenase (1) NF-κB (3) NO Synthase (1) NOD-like Receptor (NLR) (1) PERK (1) PGE synthase (1) PPAR (48) Pyroptosis (1) Reactive Oxygen Species (ROS) (3) Reference Standards (11) Sirtuin (1) SOD (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (25) Infection (1) Inflammation/Immunology (12) Metabolic Disease (26) Neurological Disease (1)

By Targets:

Akt (1)

Apoptosis (4)

Arrestin (1)

Autophagy (7)

Calcium Channel (2)

Cytochrome P450 (6)

DNA/RNA Synthesis (1)

Drug Intermediate (2)

Endogenous Metabolite (2)

Epoxide Hydrolase (3)

ERK (3)

FLAP (3)

Free Fatty Acid Receptor (1)

GPR35 (1)

Histone Demethylase (1)

Isotope-Labeled Compounds (5)

Keap1-Nrf2 (1)

Leukotriene Receptor (3)

Lipoxygenase (1)

NF-κB (3)

NO Synthase (1)

NOD-like Receptor (NLR) (1)

PERK (1)

PGE synthase (1)

PPAR (48)

Pyroptosis (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (11)

Sirtuin (1)

SOD (1)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (13)

Cardiovascular Disease (25)

Infection (1)

Inflammation/Immunology (12)

Metabolic Disease (26)

Neurological Disease (1)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17356

Fenofibrate Maximum Cited Publications 33 Publications Verification	PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-16995

Pirinixic acid Maximum Cited Publications 33 Publications Verification Wy-14643	PPAR	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Wy-14643) is a potent agonist of *PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα* and PPARγ, and 5.0 μM, 60 μM, 35 μM for human *PPARα, PPARγ and PPAR*δ, respectively.

HY-13861

GW7647 20+ Cited Publications	PPAR	Cardiovascular Disease
GW7647 is a potent *PPARα* agonist, with EC₅₀s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-B0637

Bezafibrate 10+ Cited Publications BM15075	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for *human PPARα*, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPAR*δ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-13928

GW0742 15+ Cited Publications GW610742	PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 is a potent PPARβ and PPARδ agonist, with an IC₅₀ of 1 nM for human PPARδ in binding assay, and EC₅₀s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

HY-14166

MK-886 10+ Cited Publications L 663536	FLAP Leukotriene Receptor PPAR Apoptosis	Cancer
MK-886 (L 663536) is a potent, cell-permeable and orally active FLAP (IC₅₀ of 30 nM) and leukotriene biosynthesis (IC₅₀s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive *PPARα* antagonist and can induce apoptosis .

HY-17444

Tesaglitazar	PPAR	Metabolic Disease Cancer
Tesaglitazar is a dual-target PPARα/γ agonist with an EC₅₀ of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain .

HY-N0515

Ophiopogonin D 1 Publications Verification	PPAR NF-κB Calcium Channel Reactive Oxygen Species (ROS) ERK	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Ophiopogonin D can be isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C₂₉ steroidal glycoside. Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca ²⁺ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D can inhibit isteoclastic differentiation in RAW264.7 cells. Ophiopogonin D has protective effect as an antioxidant in H₂O₂-induced endothelial injury. Ophiopogonin D blocks ERK signaling cascades. Ophiopogonin D alleviates high-fat diet-induced metabolic syndrome and changes the structure of gut microbiota in mice. Ophiopogonin D has been used against inflammatory, metabolic and cardiovascular diseases .

HY-W018158

DHICA 5,6-Dihydroxyindole-2-carboxylic acid	Endogenous Metabolite GPR35 Arrestin DNA/RNA Synthesis Drug Intermediate SOD	Cancer
DHICA (5,6-Dihydroxyindole-2-carboxylic acid) is an eumelanin building block, GPR35 agonist and melanin synthesis intermediate. DHICA activates GPR35, triggering dynamic mass redistribution and β-arrestin translocation. DHICA interacts with DNA and interferes with Fpg activity . DHICA promotes the generation of single-strand breaks in plasmid DNA. DHICA increases the activity and expression levels of SOD and Catalase. DHICA is applicable to research related to skin cancer and colon cancer .

HY-N1990

Gypenoside XLIX 2 Publications Verification	PPAR Sirtuin Keap1-Nrf2 Toll-like Receptor (TLR) NF-κB Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Apoptosis Pyroptosis Autophagy	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a K_a value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a *PPAR-α* agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation .

HY-W081067

Perfluoro(2-methyl-3-oxahexanoic) acid HFPO-DA	PPAR	Infection
Perfluoro (2-methyl-3-oxahexanoic) acid (HFPO-DA) is an orally active *PPARα* agonist with an EC₅₀ of 2.1 μM for human *PPARα*. Perfluoro (2-methyl-3-oxahexanoic) acid induces peroxisome proliferation and increases the levels of proinflammatory mediators. It impairs intestinal barrier function and disrupts cecal flora balance. Perfluoro (2-methyl-3-oxahexanoic) acid is applicable to research related to developmental toxicity, hepatotoxicity and intestinal toxicity .

HY-B0287

Clofibrate 4 Publications Verification	PPAR	Metabolic Disease
Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ～500 μM for murine PPARα* and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.

HY-114263

NXT629 4 Publications Verification	PPAR	Cancer
NXT629 is a potent, selective, and competitive *PPAR-α* antagonist, with an IC₅₀ of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC₅₀s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively . NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models .

HY-10678

BMS-687453 3 Publications Verification	PPAR	Cardiovascular Disease
BMS-687453 is a potent and selective *PPARα* agonist, with an EC₅₀ and IC₅₀ of 10 nM and 260 nM for human *PPARα* and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.

HY-17445

Muraglitazar BMS-298585	PPAR	Metabolic Disease
Muraglitazar is a PPAR α/γ dual agonist for the research of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα (EC₅₀ = 320 nM) and PPARγ(EC₅₀ = 110 nM) .

HY-121538

CUDA 1 Publications Verification	Epoxide Hydrolase PPAR	Cardiovascular Disease
CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .

HY-W203683

Perfluorononanoic acid PFNA; Heptadecafluorononanoic acid	PPAR PERK	Metabolic Disease
Perfluorononanoic acid (PFNA) is an orally active PPARα activator. Perfluorononanoic acid activates PPARα-mediated gene expression, including upregulating target genes associated with lipid metabolism and triglyceride storage. Perfluorononanoic acid exhibits certain developmental and reproductive toxicity. Perfluorononanoic acid causes hepatomegaly in pregnant mice, induces high postnatal mortality in neonatal mice, and leads to dose-dependent delays in eye-opening time and puberty onset in mouse offspring .

HY-50665

LY518674 LY-674	PPAR	Metabolic Disease
LY518674 is a potent, selective *PPARα* agonist, with an EC₅₀ of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis .

HY-17356S

Fenofibrate-d6	Isotope-Labeled Compounds PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-17356R

Fenofibrate (Standard) Maximum Cited Publications 33 Publications Verification	Reference Standards PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate (Standard) is the analytical standard of Fenofibrate. This product is intended for research and analytical applications. Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-168376

9(10)-Nitrooleate 9(10)-Nitrated oleic acid	PPAR ERK Akt NO Synthase	Metabolic Disease Inflammation/Immunology
9 (10)-Nitrooleate (9(10)-Nitrated oleic acid) is an endogenous lipid signaling mediator with vasoprotective effects. 9 (10)-Nitrooleate enhances enzymatic activity and improves nitric oxide bioavailability by inducing phosphorylation of Akt and ERK1/2, regulating the multi-site phosphorylation status of eNOS and optimizing its interaction with Hsp90. 9 (10)-Nitrooleate also activates PPARα, PPARδ and PPARγ receptors, thereby regulating adipogenesis, glucose uptake and inflammation-related gene expression, and exhibits immunosuppressive effects by inhibiting neutrophil migration and cytokine secretion. 9 (10)-Nitrooleate is widely used in studies of sepsis and related inflammatory diseases .

HY-B0637S

Bezafibrate-d6	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-113820

AZD4619	PPAR	Metabolic Disease
AZD4619 is an orally active, selective peroxisome proliferator-activated receptor α (PPARα) agonist. AZD4619 increases alanine aminotransferase 1 (ALT1) protein expression in a dose-dependent manner in human, but not in rat primary hepatocytes. AZD4619 is a lipid-lowering drug .

HY-111140

YS121	PGE synthase Lipoxygenase PPAR	Inflammation/Immunology
YS121 is a dual inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1; IC₅₀ = 3.4 μM) and 5-lipoxygenase (5-LOX; IC₅₀ = 6.5 μM). YS121 exhibits direct, reversible, and specific binding to mPGES-1 (K_D = 10-14 μM) . YS121 dose-dependently reduces PGE₂ production with an EC₅₀ of 12 μM in IL-1β-stimulated A549 cells . YS121 (compound 9) activates *PPAR-α and -γ (EC₅₀* = 1 and 3.6 μM, respectively) . YS121 exhibits anti-inflammatory efficiency in human whole blood as well as in vivo. YS121 can be used for pleurisy research .

HY-N0515R

Ophiopogonin D (Standard)	Reference Standards PPAR NF-κB Calcium Channel ERK Reactive Oxygen Species (ROS)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Ophiopogonin D (Standard) is the analytical standard of Ophiopogonin D. This product is intended for research and analytical applications. Ophiopogonin D can be isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside. Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D can inhibit isteoclastic differentiation in RAW264.7 cells. Ophiopogonin D has protective effect as an antioxidant in H₂O₂-induced endothelial injury. Ophiopogonin D blocks ERK signaling cascades. Ophiopogonin D alleviates high-fat diet-induced metabolic syndrome and changes the structure of gut microbiota in mice. Ophiopogonin D has been used against inflammatory, metabolic and cardiovascular diseases .

HY-B0287R

Clofibrate (Standard) 4 Publications Verification	Reference Standards PPAR	Metabolic Disease
Clofibrate (Standard) is the analytical standard of Clofibrate. This product is intended for research and analytical applications. Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ～500 μM for murine PPARα* and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.

HY-121538A

CUDA disodium 1 Publications Verification	Epoxide Hydrolase PPAR	Cardiovascular Disease
CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease .

HY-U00014

AVE-8134	PPAR	Metabolic Disease
AVE-8134 is a potent *PPARα* agonist, with EC₅₀ values of 100 and 3000 nM for human and rodent PPARα receptor, respectively.

HY-117196

GW 9578 1 Publications Verification	PPAR	Metabolic Disease Inflammation/Immunology
GW9578 is a subtype-selective *PPARα* agonist (EC₅₀s of 5 and 50 nM for murine and human PPAR-α) with potent lipid-lowering activity .

HY-101649

Imiglitazar TAK-559	PPAR	Cardiovascular Disease
Imiglitazar (TAK559) is a potent and dual human *PPARα* and PPARγ1 agonist with EC₅₀ values of 67 and 31 nM.

HY-13928R

GW0742 (Standard) GW610742 (Standard)	PPAR Reference Standards	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 (Standard) is the analytical standard of GW0742. This product is intended for research and analytical applications. GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

HY-14166A

MK-886 sodium salt L 663536 sodium salt	PPAR Apoptosis Leukotriene Receptor FLAP	Cancer
MK-886 (L 663536) sodium salt is a potent, cell-permeable and orally active FLAP (IC₅₀ of 30 nM) and leukotriene biosynthesis (IC₅₀s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 sodium salt is also a non-competitive *PPARα* antagonist and can induce apoptosis .

HY-14166R

MK-886 (Standard) L 663536 (Standard)	FLAP Leukotriene Receptor PPAR Apoptosis Reference Standards	Cancer
MK-886 (Standard) is the analytical standard of MK-886. This product is intended for research and analytical applications. MK-886 (L 663536) is a potent, cell-permeable and orally active FLAP (IC50 of 30 nM) and leukotriene biosynthesis (IC50s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive PPARα antagonist and can induce apoptosis .

HY-17356G

Fenofibrate	Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-111141

AM-3189	Free Fatty Acid Receptor	Metabolic Disease
AM-3189 is an orally active and selective GPR40 agonist with EC₅₀ values in buffer solution and in 100% human serum of 33 nM and 10 μM respectively. AM-3189 shows no significant activity on GPR41 and GPR43, and no agonistic activity on PPAR-α, -δ, and -γ. AM-3189 enhances glucose-stimulated insulin secretion by activating GPR40 on pancreatic β cells. AM-3189 has extremely low penetration into the central nervous system and significantly reduces blood glucose levels in two humanized GPR40 mouse models. AM-3189 can be used for the study of type 2 diabetes .

HY-16995R

Pirinixic acid (Standard) Wy-14643 (Standard)	PPAR Reference Standards	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Standard) is the analytical standard of Pirinixic acid. This product is intended for research and analytical applications. Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-B0287S

Clofibrate-d4	PPAR	Metabolic Disease
Clofibrate-d₄ is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.

HY-115357

BMS711939	PPAR	Metabolic Disease
BMS711939 is a selective agonist for peroxisome proliferator-activated receptor α (PPAR α), with EC₅₀ of 4 nM and 4.5 μM, for human PPARα and human PPARγ. BMS711939 exhibits good pharmacokinetic characters in rats models. BMS711939 increases HDL cholesterol, reduces LDL cholesterol and triglycerides .

HY-13861R

GW7647 (Standard)	PPAR	Cardiovascular Disease
GW7647 (Standard) is the analytical standard of GW7647. This product is intended for research and analytical applications. GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-162123

PPARα/δ agonist 2	PPAR	Inflammation/Immunology
PPARα/δ agonist 2 (compound 14) is a potent *PPARα* and PPARδ agonist with EC₅₀s of 3255 nM and 1475 nM for human PPARα and PPARβ/δ, respectively. PPARα/δ agonist 2 shows anti-inflammatory effects .

HY-B0637S1

Bezafibrate-d4 BM15075-d₄	Isotope-Labeled Compounds PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637R

Bezafibrate (Standard) BM15075 (Standard)	Reference Standards PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate (Standard) is the analytical standard of Bezafibrate. This product is intended for research and analytical applications. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for *human PPARα*, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPAR*δ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637S2

Bezafibrate-13C6 BM15075-¹³C₆	Isotope-Labeled Compounds PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate- ¹³C₆ (BM15075- ¹³C₆) is ¹³C labeled Bezafibrate. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for *human PPARα*, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPAR*δ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-121538S

CUDA-d11	Isotope-Labeled Compounds Epoxide Hydrolase PPAR	Cardiovascular Disease
CUDA-d₁₁ is deuterium labeled CUDA (HY-121538). CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .

HY-N1990R

Gypenoside XLIX (Standard)	Reference Standards PPAR	Cardiovascular Disease Inflammation/Immunology
Gypenoside XLIX (Standard) is the analytical standard of Gypenoside XLIX. This product is intended for research and analytical applications. Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelial cells .

HY-W027751R

2-Methylanisole (Standard)	Drug Intermediate Reference Standards	Others
Gypenoside XLIX (Standard) is the analytical standard of Gypenoside XLIX. This product is intended for research and analytical applications. Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelial cells .

HY-17356S2

Fenofibrate-13C6	Isotope-Labeled Compounds Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-17356S1

Fenofibrate-d4	PPAR Autophagy Cytochrome P450	Cardiovascular Disease
Fenofibrate-d₄ is the deuterium labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively .

HY-121888

20-HEPE	PPAR	Metabolic Disease
20-HEPE is a metabolite of eicosapentaenoic acid formed by ω-oxidation of EPA by cytochrome P450 (CYP) ω-oxidases, including human CYP4F3B. At 10 μM, it activates peroxisome proliferator-activated receptor α (PPARα) in COS-7 cells expressing a luciferase reporter gene. 20-HEPE also activates mouse transient receptor potential vanilloid receptor 1 (mTRPV1) in vitro but lacks analgesic activity in rats.

HY-113038AR

α-Hydroxyglutaric acid disodium (Standard) 2-Hydroxyglutarate disodium (Standard); 2-Hydroxyglutaric acid disodium (Standard); 2-Hydroxypentanedioic acid disodium (Standard)	Reference Standards Histone Demethylase Endogenous Metabolite	Cancer
Ophiopogonin D (Standard) is the analytical standard of Ophiopogonin D. This product is intended for research and analytical applications. Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .

Cat. No.	Product Name	Category	Target	Chemical Structure